# Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)

> **NCT05815212** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 87 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05815212
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-11
- **Primary completion:** 2022-04-04
- **Final completion:** 2022-04-04
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05815212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05815212, "Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05815212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*